A phase II efficacy study of chemo-radiotherapy in PET stage II and III Merkel cell carcinoma of the skin.

This study aims to develop a well-tolerated chemo-radiotherapy treatment for patients with Merkel Cell Carcinoma (MCC) of the skin, which achieves high rates of cancer control. The researchers will be looking at patients' quality of life in those receiving chemotherapy via a questionnaire that will be completed periodically throughout treatment and the follow-up after. The researches will also be looking at the value of using Positron Emission Tomography (PET – a type of imaging procedure that allows us to see anatomical structure and function that cannot usually be seen on a CT scan) to assist in tailoring the Radiation Therapy (RT) treatment plan to the extent of each participants disease.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

42

Closing Date of Accrual

January 2016

Trial Chairperson

Associate Professor Michael Poulsen, Mater Centre, QLD

Trial Contact

Narelle.Wallace2@health.qld.gov.au

Clinical Trial Registration

Related Post

HeSANDA database for clinical trial data
21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is

SMART trial grant
16 April, 2025

Mark Hughes Foundation grant for innovative SMART trial into brain metastases

LATEST NEWS: 15 April 2025 An innovative trial aimed